[96a5a0]: / output / allTrials / identified / NCT03641560_identified.json

Download this file

256 lines (256 with data), 11.3 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
{
"info": {
"nct_id": "NCT03641560",
"official_title": "A Multicenter Phase 4, Open-label, Single-arm, Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy",
"inclusion_criteria": "* Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.\n* Subject with established diagnosis of metastatic castration-resistant prostate carcinoma.\n* Subject is being newly initiated on Xtandi treatment (Enzalutamide).\n* Subject has an estimated life expectancy of ≥ 6 months.\n* Subject agrees not to participate in another interventional study while participating in the present study.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Subject who is not eligible to receive Xtandi as per the locally approved prescribing information.\n* Subject participating or planning to participate in any interventional drug trial during the course of this trial.\n* Subject has received investigational study within 28 days or 5 half-lives, whichever is longer, prior to screening.\n* Subject has any condition which makes the subject unsuitable for study participation.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.",
"criterions": [
{
"exact_snippets": "diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate",
"criterion": "adenocarcinoma of the prostate",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "without neuroendocrine differentiation",
"criterion": "neuroendocrine differentiation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "without ... signet cell ... histology",
"criterion": "signet cell histology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "without ... small cell histology",
"criterion": "small cell histology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Subject with established diagnosis of metastatic castration-resistant prostate carcinoma.",
"criterions": [
{
"exact_snippets": "established diagnosis of metastatic castration-resistant prostate carcinoma",
"criterion": "metastatic castration-resistant prostate carcinoma",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
}
]
},
{
"line": "* Subject is being newly initiated on Xtandi treatment (Enzalutamide).",
"criterions": [
{
"exact_snippets": "Subject is being newly initiated on Xtandi treatment (Enzalutamide)",
"criterion": "Xtandi treatment (Enzalutamide)",
"requirements": [
{
"requirement_type": "initiation status",
"expected_value": "newly initiated"
}
]
}
]
},
{
"line": "* Subject has an estimated life expectancy of ≥ 6 months.",
"criterions": [
{
"exact_snippets": "estimated life expectancy of ≥ 6 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Subject agrees not to participate in another interventional study while participating in the present study.",
"criterions": [
{
"exact_snippets": "Subject agrees not to participate in another interventional study",
"criterion": "participation in another interventional study",
"requirements": [
{
"requirement_type": "agreement",
"expected_value": false
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "Must be MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Subject who is not eligible to receive Xtandi as per the locally approved prescribing information.",
"criterions": [
{
"exact_snippets": "not eligible to receive Xtandi as per the locally approved prescribing information",
"criterion": "eligibility to receive Xtandi",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": false
}
]
}
]
},
{
"line": "* Subject participating or planning to participate in any interventional drug trial during the course of this trial.",
"criterions": [
{
"exact_snippets": "Subject participating ... in any interventional drug trial",
"criterion": "participation in interventional drug trial",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "planning to participate in any interventional drug trial",
"criterion": "planned participation in interventional drug trial",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Subject has received investigational study within 28 days or 5 half-lives, whichever is longer, prior to screening.",
"criterions": [
{
"exact_snippets": "Subject has received investigational study within 28 days or 5 half-lives, whichever is longer, prior to screening.",
"criterion": "receipt of investigational study",
"requirements": [
{
"requirement_type": "time since last dose",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 28,
"unit": "days"
}
]
}
}
]
}
]
},
{
"line": "* Subject has any condition which makes the subject unsuitable for study participation.",
"criterions": [
{
"exact_snippets": "any condition which makes the subject unsuitable for study participation",
"criterion": "suitability for study participation",
"requirements": [
{
"requirement_type": "suitability",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}